Search

Your search keyword '"Labots, Mariette"' showing total 260 results
Start Over Author "Labots, Mariette"
260 results on '"Labots, Mariette"'

51. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Author

van Linde, Myra E., primary, Labots, Mariette, additional, Brahm, Cyrillo G., additional, Hovinga, Koos E., additional, De Witt Hamer, Philip C., additional, Honeywell, Richard J., additional, de Goeij-de Haas, Richard, additional, Henneman, Alex A., additional, Knol, Jaco C., additional, Peters, Godefridus J., additional, Dekker, Henk, additional, Piersma, Sander R., additional, Pham, Thang V., additional, Vandertop, William P., additional, Jiménez, Connie R., additional, and Verheul, Henk M.W., additional

Published
2022
Full Text
View/download PDF

52. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Author

Hoes, Louisa R., primary, van Berge Henegouwen, Jade M., additional, van der Wijngaart, Hanneke, additional, Zeverijn, Laurien J., additional, van der Velden, Daphne L., additional, van de Haar, Joris, additional, Roepman, Paul, additional, de Leng, Wendy J., additional, Jansen, Anne M.L., additional, van Werkhoven, Erik, additional, van der Noort, Vincent, additional, Huitema, Alwin D.R., additional, Gort, Eelke H., additional, de Groot, Jan Willem B., additional, Kerver, Emile D., additional, de Groot, Derk Jan, additional, Erdkamp, Frans, additional, Beerepoot, Laurens V., additional, Hendriks, Mathijs P., additional, Smit, Egbert F., additional, van der Graaf, Winette T.A., additional, van Herpen, Carla M.L., additional, Labots, Mariette, additional, Hoeben, Ann, additional, Morreau, Hans, additional, Lolkema, Martijn P., additional, Cuppen, Edwin, additional, Gelderblom, Hans, additional, Verheul, Henk M.W., additional, and Voest, Emile E., additional

Published
2022
Full Text
View/download PDF

54. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Author

van der Wijngaart, Hanneke, primary, Hoes, Louisa R., additional, van Berge Henegouwen, J. Maxime, additional, van der Velden, Daphne L., additional, Zeverijn, Laurien J., additional, Roepman, Paul, additional, van Werkhoven, Erik, additional, de Leng, Wendy W.J., additional, Jansen, Anne M.L., additional, Mehra, Niven, additional, Robbrecht, Debbie G.J., additional, Labots, Mariette, additional, de Groot, Derk Jan A., additional, Hoeben, Ann, additional, Hamberg, Paul, additional, Gelderblom, Hans, additional, Voest, Emile E., additional, and Verheul, Henk M.W., additional

Published
2021
Full Text
View/download PDF

56. Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics.

Author

van der Wijngaart, Hanneke, primary, Beekhof, Robin, additional, Knol, Jaco C., additional, Henneman, Alex A., additional, de Goeij - de Haas, Richard, additional, Piersma, Sander R., additional, Pham, Thang V., additional, Jimenez, Connie R., additional, Verheul, Henk M.W., additional, and Labots, Mariette, additional

Published
2021
Full Text
View/download PDF

57. Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

Author

Douma, Joeri A. J., primary, Buffart, Laurien M., additional, Sedhom, Ramy, additional, Labots, Mariette, additional, Menke-van der Houven van Oordt, Willemien C., additional, Skardhamar, Mikkjal, additional, De Felice, Anthony, additional, Lee, Esther, additional, Dharmaraj, Divya, additional, Azad, Nilofer S., additional, Carducci, Michael A., additional, and Verheul, Henk M. W., additional

Published
2021
Full Text
View/download PDF

58. Additional file 4 of Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients

Author

Buffart, Tineke E., Oord, Rosanne A. H. M. Van Den, Berg, Adriënne Van Den, Hilhorst, Riet, Bastiaensen, Niek, Pruijt, Hans F. M., Brule, Adriaan Van Den, Nooijen, Peet, Labots, Mariette, Haas, Richard R. De Goeij-De, Dekker, Henk, Piersma, Sander R., Pham, Thang V., Leij, Theo Van Der, Wijn, Rik De, Ruijtenbeek, Rob, Jiménez, Connie R., and Verheul, Henk M. W.

Subjects
sense organs
Abstract

Additional file 4: Table S1. Peptides significantly changing with 180 min of CIT (p 2), measured with a peptide microarray for patients 1–4 using a One-Way ANOVA test. In patient 5 none of the peptides were significantly changing with CIT. Peptides significantly altered, in patients 1–5 combined using a Mixed Model analysis, are shown in bold. UniProt Accession numbers, protein IDs and peptide sequence are given. Table S2. Phosphopeptides significantly changing with CIT (p

Published
2021
Full Text
View/download PDF

59. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer

Author

MS Medische Oncologie, Cancer, Guman, Noori A M, van Geffen, Roos J, Mulder, Frits I, van Haaps, Thijs F, Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A, de Vos, Filip Y F L, Ten Tije, Albert J, Beerepoot, Laurens V, Tjan-Heijnen, Vivianne C G, van Laarhoven, Hanneke W M, Hamberg, Paul, Vulink, Annelie J E, Los, Maartje, Zwinderman, Aeilko H, Ferwerda, Bart, Lolkema, Martijn P J K, Steeghs, Neeltje, Büller, Harry R, Kamphuisen, Pieter W, van Es, Nick, MS Medische Oncologie, Cancer, Guman, Noori A M, van Geffen, Roos J, Mulder, Frits I, van Haaps, Thijs F, Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A, de Vos, Filip Y F L, Ten Tije, Albert J, Beerepoot, Laurens V, Tjan-Heijnen, Vivianne C G, van Laarhoven, Hanneke W M, Hamberg, Paul, Vulink, Annelie J E, Los, Maartje, Zwinderman, Aeilko H, Ferwerda, Bart, Lolkema, Martijn P J K, Steeghs, Neeltje, Büller, Harry R, Kamphuisen, Pieter W, and van Es, Nick

Published
2021

60. Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types

Author

Pathologie Pathologen staf, Cancer, Pathologie Moleculair, van der Wijngaart, Hanneke, Hoes, Louisa R, van Berge Henegouwen, J Maxime, van der Velden, Daphne L, Zeverijn, Laurien J, Roepman, Paul, van Werkhoven, Erik, de Leng, Wendy W J, Jansen, Anne M L, Mehra, Niven, Robbrecht, Debbie G J, Labots, Mariette, de Groot, Derk Jan A, Hoeben, Ann, Hamberg, Paul, Gelderblom, Hans, Voest, Emile E, Verheul, Henk M W, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, van der Wijngaart, Hanneke, Hoes, Louisa R, van Berge Henegouwen, J Maxime, van der Velden, Daphne L, Zeverijn, Laurien J, Roepman, Paul, van Werkhoven, Erik, de Leng, Wendy W J, Jansen, Anne M L, Mehra, Niven, Robbrecht, Debbie G J, Labots, Mariette, de Groot, Derk Jan A, Hoeben, Ann, Hamberg, Paul, Gelderblom, Hans, Voest, Emile E, and Verheul, Henk M W

Published
2021

61. Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Author

CMM Groep Cuppen, Externen Med. Onco, MS Medische Oncologie, Cancer, CMM, Mendelaar, Pauline A J, Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P, Cirkel, Geert A, van Rooijen, Johan M, Ten Tije, Albert J, Lolkema, Martijn P, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W M, Wilting, Saskia M, CMM Groep Cuppen, Externen Med. Onco, MS Medische Oncologie, Cancer, CMM, Mendelaar, Pauline A J, Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P, Cirkel, Geert A, van Rooijen, Johan M, Ten Tije, Albert J, Lolkema, Martijn P, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W M, and Wilting, Saskia M

Published
2021

63. Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer

Author

Gootjes, Elske C, van der Stok, Eric P, Buffart, Tineke E, Bakkerus, Lotte, Labots, Mariette, Zonderhuis, Barbara M, Tuynman, Jurriaan B, Meijerink, Martijn R, van de Ven, Peter M, Haasbeek, Cornelis J A, Ten Tije, Albert J, de Groot, Jan-Willem B, Hendriks, Mathijs P, van Meerten, Esther, Nuyttens, Joost J M E, Grunhagen, Dirk J, Verhoef, Cornelis, Verheul, Henk M W, Gootjes, Elske C, van der Stok, Eric P, Buffart, Tineke E, Bakkerus, Lotte, Labots, Mariette, Zonderhuis, Barbara M, Tuynman, Jurriaan B, Meijerink, Martijn R, van de Ven, Peter M, Haasbeek, Cornelis J A, Ten Tije, Albert J, de Groot, Jan-Willem B, Hendriks, Mathijs P, van Meerten, Esther, Nuyttens, Joost J M E, Grunhagen, Dirk J, Verhoef, Cornelis, and Verheul, Henk M W

Abstract

INTRODUCTION: Local treatment of metastases is frequently performed in patients with multiorgan metastatic colorectal carcinoma (mCRC) analogous to selected patients with oligometastatic disease for whom this is standard of care. The ORCHESTRA trial (NCT01792934) was designed to prospectively evaluate overall survival benefit from tumor debulking in addition to chemotherapy in patients with multiorgan mCRC. Here, we report the preplanned safety and feasibility evaluation after inclusion of the first 100 patients.METHODS: Patients were eligible if at least 80% tumor debulking was deemed feasible by resection, radiotherapy and/or thermal ablative therapy. In case of clinical benefit after three or four cycles of respectively 5-fluorouracil/leucovorin or capecitabine and oxaliplatin ± bevacizumab patients were randomized to tumor debulking followed by chemotherapy in the intervention arm, or standard treatment with chemotherapy.RESULTS: Twelve patients dropped out prior to randomization for various reasons. Eighty-eight patients were randomized to the standard (n = 43) or intervention arm (n = 45). No patients withdrew after randomization. Debulking was performed in 82% (n = 37). Two patients had no lesions left to treat, five had progressive disease, and one patient died prior to local treatment. In 15 patients (40%) 21 serious adverse events related to debulking were reported. Postoperative mortality was 2.7% (n = 1). After debulking chemotherapy was resumed in 89% of patients.CONCLUSION: Tumor debulking is feasible and does not prohibit administration of palliative chemotherapy in the majority of patients with multiorgan mCRC, despite the occurrence of serious adverse events related to local treatment.IMPLICATIONS FOR PRACTICE: This first prospective randomized trial on tumor debulking in addition to chemotherapy shows that local treatment of metastases is feasible in patients with multiorgan metastatic colorectal cancer and does not p

Published
2020

64. Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome

Author

Labots, Mariette, primary, Pham, Thang V., additional, Honeywell, Richard J., additional, Knol, Jaco C., additional, Beekhof, Robin, additional, de Goeij-de Haas, Richard, additional, Dekker, Henk, additional, Neerincx, Maarten, additional, Piersma, Sander R., additional, van der Mijn, Johannes C., additional, van der Peet, Donald L., additional, Meijerink, Martijn R., additional, Peters, Godefridus J., additional, van Grieken, Nicole C.T., additional, Jiménez, Connie R., additional, and Verheul, Henk M.W., additional

Published
2020
Full Text
View/download PDF

66. Endocriene bijwerkingen van checkpointremmers

Author

Chen, Weena J Y, Krul-Poel, Yvonne H M, Roth, Chantal, Labots, Mariette, van den Eertwegh, Alfons J M, Dreijerink, Koen M A, Internal medicine, Medical oncology, CCA - Cancer biology and immunology, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

Checkpoint inhibition has emerged as a promising therapeutic strategy for several types of cancer. Immune-related adverse effects (irAEs) commonly involve the endocrine system. Distinguishing endocrine side effect-related symptoms from disease progression or treatment-related toxicity can be challenging. If not recognized in time, endocrine irAEs may be life-threatening. As the use of checkpoint inhibitors is expected to increase, there is a need for more awareness of endocrine irAEs amongst health care professionals. We describe three cases that illustrate the importance of timely recognition, patient education and the management of endocrinopathies. Two patients who were treated with the checkpoint inhibitor ipilimumab developed hypophysitis and subsequent episodes of hypocortisolism. These cases underline both the frequency of diagnostic delay and the importance of patient education with regard to glucocorticoid stress dosage. The third patient presented with diabetes mellitus after administration of nivolumab. A multidisciplinary approach is warranted to ensure optimal care for patients with endocrine irAEs.

Published
2019

67. INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases (vol 15, e8250, 2019)

Author

Beekhof, Robin, van Alphen, Carolien, Henneman, Alex A., Knol, Jaco C., Pham, Thang V., Rolfs, Frank, Labots, Mariette, Henneberry, Evan, Le Large, Tessa Y. S., de Haas, Richard R., Piersma, Sander R., Vurchio, Valentina, Bertotti, Andrea, Trusolino, Livio, Verheul, Henk M. W., Jimenez, Connie R., Medical oncology laboratory, Hematology laboratory, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Internal medicine, CCA - Cancer Treatment and quality of life, Surgery, Amsterdam Neuroscience - Neurodegeneration, and AGEM - Re-generation and cancer of the digestive system

Published
2019

68. Correction to: INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases (Molecular Systems Biology, (2019), 15, 4, (e8250), 10.15252/msb.20188250)

Author

Beekhof, Robin, van Alphen, Carolien, Henneman, Alex A., Knol, Jaco C., Pham, Thang V., Rolfs, Frank, Labots, Mariette, Henneberry, Evan, le Large, Tessa Y. S., de Haas, Richard R., Piersma, Sander R., Vurchio, Valentina, Bertotti, Andrea, Trusolino, Livio, Verheul, Henk M. W., Jimenez, Connie R., Medical oncology laboratory, Hematology laboratory, CCA - Imaging and biomarkers, Medical oncology, Surgery, AGEM - Re-generation and cancer of the digestive system, and Amsterdam Neuroscience - Neurodegeneration

Abstract

The authors recently noticed that the affiliations for Valentina Vurchio, Andrea Bertotti, and Livio Trusolino were listed incorrectly. The correct author affiliation is shown here and has been corrected in the original article. The authors apologize for this error.

Published
2019

69. Pan-cancer whole-genome analyses of metastatic solid tumours

Author

CMM Groep Cuppen, MS Medische Oncologie, Cancer, CMM, Priestley, Peter, Baber, Jonathan, Lolkema, Martijn P, Steeghs, Neeltje, de Bruijn, Ewart, Shale, Charles, Duyvesteyn, Korneel, Haidari, Susan, van Hoeck, Arne, Onstenk, Wendy, Roepman, Paul, Voda, Mircea, Bloemendal, Haiko J, Tjan-Heijnen, Vivianne C G, van Herpen, Carla M L, Labots, Mariette, Witteveen, Petronella O, Smit, Egbert F, Sleijfer, Stefan, Voest, Emile E, Cuppen, Edwin, CMM Groep Cuppen, MS Medische Oncologie, Cancer, CMM, Priestley, Peter, Baber, Jonathan, Lolkema, Martijn P, Steeghs, Neeltje, de Bruijn, Ewart, Shale, Charles, Duyvesteyn, Korneel, Haidari, Susan, van Hoeck, Arne, Onstenk, Wendy, Roepman, Paul, Voda, Mircea, Bloemendal, Haiko J, Tjan-Heijnen, Vivianne C G, van Herpen, Carla M L, Labots, Mariette, Witteveen, Petronella O, Smit, Egbert F, Sleijfer, Stefan, Voest, Emile E, and Cuppen, Edwin

Published
2019

70. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

Author

CMM Groep Cuppen, Cancer, CMM, Angus, Lindsay, Smid, Marcel, Wilting, Saskia M, van Riet, Job, Van Hoeck, Arne, Nguyen, Luan, Nik-Zainal, Serena, Steenbruggen, Tessa G, Tjan-Heijnen, Vivianne C G, Labots, Mariette, van Riel, Johanna M G H, Bloemendal, Haiko J, Steeghs, Neeltje, Lolkema, Martijn P, Voest, Emile E, van de Werken, Harmen J G, Jager, Agnes, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W M, CMM Groep Cuppen, Cancer, CMM, Angus, Lindsay, Smid, Marcel, Wilting, Saskia M, van Riet, Job, Van Hoeck, Arne, Nguyen, Luan, Nik-Zainal, Serena, Steenbruggen, Tessa G, Tjan-Heijnen, Vivianne C G, Labots, Mariette, van Riel, Johanna M G H, Bloemendal, Haiko J, Steeghs, Neeltje, Lolkema, Martijn P, Voest, Emile E, van de Werken, Harmen J G, Jager, Agnes, Cuppen, Edwin, Sleijfer, Stefan, and Martens, John W M

Published
2019

72. Abstract CT117: A Phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: The STELLAR study

Author

Brahm, Cyrillo G., primary, Linde, Myra E. van, additional, Labots, Mariette, additional, Kouwenhoven, Mathilde C., additional, Aliaga, Esther Sanchez, additional, Enting, Roelien H., additional, Appelman, Auke P., additional, Nuver, Janine, additional, Walenkamp, Annemiek M., additional, and Verheul, Henk M., additional

Published
2019
Full Text
View/download PDF

75. Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study

Author

Labots, Mariette, Mijn, Johannes C. Van der, Dekker, Henk, Ruijter, Rita, Pham, Thang V., Vliet, Hans J. Van der, Hoeven, J.J.M. van der, Meijer, Gerrit A., Verheul, H.M.W., Labots, Mariette, Mijn, Johannes C. Van der, Dekker, Henk, Ruijter, Rita, Pham, Thang V., Vliet, Hans J. Van der, Hoeven, J.J.M. van der, Meijer, Gerrit A., and Verheul, H.M.W.

Abstract

Item does not contain fulltext

Published
2018

76. Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.

Author

Gootjes, Elske C., Stok, Eric P., Buffart, Tineke E., Bakkerus, Lotte, Labots, Mariette, Zonderhuis, Barbara M., Tuynman, Jurriaan B., Meijerink, Martijn R., Ven, Peter M., Haasbeek, Cornelis J.A., ten Tije, Albert J., Groot, Jan‐Willem B., Hendriks, Mathijs P., Meerten, Esther, Nuyttens, Joost J.M.E., Grunhagen, Dirk J., Verhoef, Cornelis, and Verheul, Henk M.W.

Subjects
CANCER chemotherapy, CLINICAL trials, COLON tumors, LONGITUDINAL method, METASTASIS, RECTUM tumors, STATISTICAL sampling, SURVIVAL, PILOT projects, RANDOMIZED controlled trials, TREATMENT effectiveness, ABLATION techniques, ADVERSE health care events, DESCRIPTIVE statistics
Abstract

Introduction: Local treatment of metastases is frequently performed in patients with multiorgan metastatic colorectal carcinoma (mCRC) analogous to selected patients with oligometastatic disease for whom this is standard of care. The ORCHESTRA trial (NCT01792934) was designed to prospectively evaluate overall survival benefit from tumor debulking in addition to chemotherapy in patients with multiorgan mCRC. Here, we report the preplanned safety and feasibility evaluation after inclusion of the first 100 patients. Methods: Patients were eligible if at least 80% tumor debulking was deemed feasible by resection, radiotherapy and/or thermal ablative therapy. In case of clinical benefit after three or four cycles of respectively 5‐fluorouracil/leucovorin or capecitabine and oxaliplatin ± bevacizumab patients were randomized to tumor debulking followed by chemotherapy in the intervention arm, or standard treatment with chemotherapy. Results: Twelve patients dropped out prior to randomization for various reasons. Eighty‐eight patients were randomized to the standard (n = 43) or intervention arm (n = 45). No patients withdrew after randomization. Debulking was performed in 82% (n = 37). Two patients had no lesions left to treat, five had progressive disease, and one patient died prior to local treatment. In 15 patients (40%) 21 serious adverse events related to debulking were reported. Postoperative mortality was 2.7% (n = 1). After debulking chemotherapy was resumed in 89% of patients. Conclusion: Tumor debulking is feasible and does not prohibit administration of palliative chemotherapy in the majority of patients with multiorgan mCRC, despite the occurrence of serious adverse events related to local treatment. Implications for Practice: This first prospective randomized trial on tumor debulking in addition to chemotherapy shows that local treatment of metastases is feasible in patients with multiorgan metastatic colorectal cancer and does not prohibit administration of palliative systemic therapy, despite the occurrence of serious adverse events related to local treatment. The trial continues accrual, and overall survival (OS) data and quality of life assessment are collected to determine whether the primary aim of >6 months OS benefit with preserved quality of life will be met. This will support evidence‐based decision making in multidisciplinary colorectal cancer care and can be readily implemented in daily practice. The ORCHESTRA trial was designed to prospectively evaluate overall survival benefit from tumor debulking in addition to chemotherapy in patients with multi‐organ metastatic colorectal cancer. This article reports the preplanned safety and feasibility evaluation after inclusion of the first 100 patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

77. Pan-cancer whole genome analyses of metastatic solid tumors

Author

Priestley, Peter, primary, Baber, Jonathan, additional, Lolkema, Martijn P., additional, Steeghs, Neeltje, additional, de Bruijn, Ewart, additional, Shale, Charles, additional, Duyvesteyn, Korneel, additional, Haidari, Susan, additional, van Hoeck, Arne, additional, Onstenk, Wendy, additional, Roepman, Paul, additional, Voda, Mircea, additional, Bloemendal, Haiko J., additional, Tjan-Heijnen, Vivianne C.G., additional, van Herpen, Carla M.L., additional, Labots, Mariette, additional, Witteveen, Petronella O., additional, Smit, Egbert F., additional, Sleijfer, Stefan, additional, Voest, Emile E., additional, and Cuppen, Edwin, additional

Published
2018
Full Text
View/download PDF

78. Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study

Author

Labots, Mariette, primary, Van der Mijn, Johannes C., additional, Dekker, Henk, additional, Ruijter, Rita, additional, Pham, Thang V., additional, Van der Vliet, Hans J., additional, Van der Hoeven, Jacobus J.M., additional, Meijer, Gerrit A., additional, and Verheul, Henk M.W., additional

Published
2018
Full Text
View/download PDF

79. INKA, an integrative data analysis pipeline for phosphoproteomic inference of active phosphokinases

Author

Pham, Thang V., primary, Beekhof, Robin, additional, van Alphen, Carolien, additional, Knol, Jaco C., additional, Henneman, Alex A., additional, Rolfs, Frank, additional, Labots, Mariette, additional, Henneberry, Evan, additional, Le Large, Tessa Y.S., additional, de Haas, Richard R., additional, Piersma, Sander R., additional, Verheul, Henk M.W., additional, and Jimenez, Connie R., additional

Published
2018
Full Text
View/download PDF

83. High-dose, intermittent sunitinib as an alternative treatment strategy

Author

Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Voortman, Johannes, Griffioen, Arjan W., Labots, Mariette, Luik, Anne Marije, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W., Medical oncology, CCA - Innovative therapy, and Medical oncology laboratory

Published
2014

84. Abstract 880: Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab

Author

Beekhof, Robin, primary, Labots, Mariette, additional, Knol, Jaco C., additional, Schelfhorst, Tim R.A., additional, van Grieken, Nicole, additional, Piersma, Sander R., additional, Pham, Thang V., additional, Bertotti, Andrea, additional, Trusolino, Livio, additional, Verheul, Henk M.W., additional, and Jiménez, Connie R., additional

Published
2016
Full Text
View/download PDF

85. Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.

Author

Labots, Mariette, primary, Beekhof, Robin, additional, Knol, Jaco C., additional, Neerincx, Maarten, additional, de Haas, Richard R., additional, Dekker, Henk, additional, Pham, Thang V., additional, Piersma, Sander R., additional, Henneberry, Evan, additional, Van der Mijn, Johannes C., additional, Rovithi, Maria, additional, Van der Peet, Donald L., additional, Meijerink, Martijn R., additional, van Grieken, Nicole C.T., additional, Jiménez, Connie R., additional, and Verheul, Henk M.W., additional

Published
2016
Full Text
View/download PDF

86. Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.

Author

Safran, Howard, Cassier, Philippe Alexandre, Vicier, Cecile, Forget, Frederic, Gomez-Roca, Carlos A., Penel, Nicolas, Campone, Mario, Romano, Emanuela, Valerin, Jennifer Brooke, Jerusalem, Guy Heinrich Maria, El-Khoueiry, Anthony B., Galsky, Matt D., Bruno, Debora S., Schröder, David, Labots, Mariette, Rinaldi, Stefano, Holdorf, Amy, Kivovich, Violetta, Cuillerot, Jean-Marie, and Subbiah, Vivek

Published
2023
Full Text
View/download PDF

87. Jonge vrouwen met hypertensie: denk aan 'de pil'

Author

Labots, Mariette, Kooter, Jos, Serné, Erik, Smulders, Yvo, Medical oncology laboratory, and Internal medicine

Abstract

Three women, aged 18, 31 and 36 years, presented with hypertension while taking oral contraceptives. Each patient had received antihypertensive drugs. Blood pressure returned to normal within weeks of cessation of oral contraceptives. Although the reduction in hormone content seems to have reduced the risk of oral contraceptive-induced hypertension, there is still an increased risk. As the prevalence of hypertension in women aged under 45 is low, the possibility that the hypertension is caused by contraceptives should be considered in women of childbearing age. Discontinuation may cause a significant decrease in blood pressure and should be encouraged before commencing antihypertensive agents. Alternative methods of contraception include the progestogen-only pill or a mechanical contraceptive device.

Published
2010

88. Abstract 2007: Phosphoproteomics scaled-down to tumor biopsies for future TKI treatment selection

Author

Labots, Mariette, primary, Van der Mijn, Johannes C., additional, Piersma, Sander R., additional, De Haas, Richard R., additional, Beekhof, Robin, additional, Pham, Thang V., additional, Knol, Jaco C., additional, de Reus, Inge, additional, van Grieken, Nicole C.T., additional, Meijer, Gerrit A., additional, Jimenez, Connie R., additional, and Verheul, Henk M.W., additional

Published
2015
Full Text
View/download PDF

89. [Hypertension in young women:remember oral contraceptives]

Author

Labots, Mariette, Kooter, Jos, Serné, Erik, and Smulders, Yvo

Abstract

Three women, aged 18, 31 and 36 years, presented with hypertension while taking oral contraceptives. Each patient had received antihypertensive drugs. Blood pressure returned to normal within weeks of cessation of oral contraceptives. Although the reduction in hormone content seems to have reduced the risk of oral contraceptive-induced hypertension, there is still an increased risk. As the prevalence of hypertension in women aged under 45 is low, the possibility that the hypertension is caused by contraceptives should be considered in women of childbearing age. Discontinuation may cause a significant decrease in blood pressure and should be encouraged before commencing antihypertensive agents. Alternative methods of contraception include the progestogen-only pill or a mechanical contraceptive device.

Published
2010

90. A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.

Author

Rovithi, Maria, primary, Voortman, Johannes, additional, Luik, Anne Marije, additional, Ruijter, Rita, additional, de Haas, Richard, additional, Honeywell, Richard, additional, Labots, Mariette, additional, Poel, Dennis, additional, Peters, Godefridus J., additional, Griffioen, Arjan W., additional, and Verheul, Henk M.W., additional

Published
2015
Full Text
View/download PDF

92. Genomic landscape of metastatic colorectal cancer

Author

Haan, Josien C., primary, Labots, Mariette, additional, Rausch, Christian, additional, Koopman, Miriam, additional, Tol, Jolien, additional, Mekenkamp, Leonie J. M., additional, van de Wiel, Mark A., additional, Israeli, Danielle, additional, van Essen, Hendrik F., additional, van Grieken, Nicole C. T., additional, Voorham, Quirinus J. M., additional, Bosch, Linda J. W., additional, Qu, Xueping, additional, Kabbarah, Omar, additional, Verheul, Henk M. W., additional, Nagtegaal, Iris D., additional, Punt, Cornelis J. A., additional, Ylstra, Bauke, additional, and Meijer, Gerrit A., additional

Published
2014
Full Text
View/download PDF

96. High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection

Author

Labots, Mariette, primary, Buffart, Tineke E., additional, Haan, Josien C., additional, van Grieken, Nicole C. T., additional, Tijssen, Marianne, additional, van de Velde, Cornelis J. H., additional, Grabsch, Heike I., additional, Ylstra, Bauke, additional, Carvalho, Beatriz, additional, Fijneman, Remond J. A., additional, Verheul, Henk M. W., additional, and Meijer, Gerrit A., additional

Published
2013
Full Text
View/download PDF

97. Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts).

Author

Kim, Jenny J., primary, Labots, Mariette, additional, Marchionni, Luigi, additional, Begum, Shahnaz, additional, Meijer, Gerrit A., additional, Verheul, Henk M.W., additional, Carducci, Michael Anthony, additional, Hammers, Hans J., additional, Allaf, Mohammad, additional, Netto, George J., additional, and Hoque, Mohammad, additional

Published
2013
Full Text
View/download PDF

98. Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.

Author

Labots, Mariette, primary, Neerincx, Maarten, additional, Van der Mijn, Johannes C., additional, Dekker, Henk, additional, Honeywell, Richard, additional, Rovithi, Maria, additional, Gotink, Kristy, additional, Voebel-De Jong, Margreet, additional, Van der Peet, Donald L., additional, Meijerink, Martijn R., additional, Meijer, Gerrit A., additional, Jiménez, Connie R., additional, Peters, Godefridus J, additional, and Verheul, Henk M.W., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results